These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557 [Abstract] [Full Text] [Related]
4. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Sanders SL, Agwan S, Hassan M, van Driel ML, Del Mar CB. Cochrane Database Syst Rev; 2019 Aug 26; 8(8):CD009417. PubMed ID: 31446622 [Abstract] [Full Text] [Related]
8. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis. Sun M, Lai H, Na F, Li S, Qiu X, Tian J, Zhang Z, Ge L. JAMA Netw Open; 2023 Feb 01; 6(2):e230023. PubMed ID: 36800182 [Abstract] [Full Text] [Related]
12. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep 01; 102(3 Pt 1):531-7. PubMed ID: 9738173 [Abstract] [Full Text] [Related]
13. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Robinson KA, Odelola OA, Saldanha IJ. Cochrane Database Syst Rev; 2014 May 22; (5):CD007743. PubMed ID: 24851825 [Abstract] [Full Text] [Related]
14. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Robinson KA, Odelola OA, Saldanha IJ, McKoy NA. Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007743. PubMed ID: 22336832 [Abstract] [Full Text] [Related]
18. Sedatives for opioid withdrawal in newborn infants. Zankl A, Martin J, Davey JG, Osborn DA. Cochrane Database Syst Rev; 2021 May 18; 5(5):CD002053. PubMed ID: 34002380 [Abstract] [Full Text] [Related]
19. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Man WH, Scheltema NM, Clerc M, van Houten MA, Nibbelke EE, Achten NB, Arp K, Sanders EAM, Bont LJ, Bogaert D. Lancet Respir Med; 2020 Oct 18; 8(10):1022-1031. PubMed ID: 32203712 [Abstract] [Full Text] [Related]